Skip to Main Content

Paper Details

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients.
Ther Drug Monit
1
2024
Author NameAffiliation
Neeltje SteeghsNetherlands Cancer Institute-Antoni van Leeuwenhoek
  • 1 - 1

Datasets

Release 1.2